Formulation of lyophilized oily-core poly-Ɛ-caprolactone nanocapsules to improve oral bioavailability of Olmesartan Medoxomil

References

• Food and Drug Administration and the Department of Health and Human Services. Notice. guidance for industry on hypertension indication: drug labeling for cardiovascular outcome claims. 2011;14024:1–12.
   Google Scholar
• Komesli Y, Ozkaya A, Ergur B, et al. Design and development of a self-microemulsifying drug delivery system of Olmesartan Medoxomil for enhanced bioavailability. Drug Dev Ind Pharm. 2019;45(8):1292–1305.
   PubMed Web of Science ®Google Scholar
• Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007;65(3):259–269.
   PubMed Web of Science ®Google Scholar
• Elgindy N, Mehanna M, Mohyeldin S. Self-assembled nano-architecture liquid crystalline particles as a promising carrier for progesterone transdermal delivery. Int J Pharm. 2016;501(1–2):167–179.
   PubMed Web of Science ®Google Scholar
• Malikmammadov E, Tanir TE, Kiziltay A, et al. PCL and PCL-based materials in biomedical applications. J Biomater Sci, Polym Ed. 2018;29(7–9):863–893.
   PubMed Web of Science ®Google Scholar
• Nasr A, Gardouh A, Ghorab M. Novel solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of Olmesartan Medoxomil: design, formulation, pharmacokinetic and bioavailability evaluation. Pharmaceutics. 2016;8(3):20–29.
   PubMed Web of Science ®Google Scholar
• Vikram K, Chander P, Varun K, et al. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability. Coll Surf B: Biointerfaces. 2017;154:10–20.
   PubMed Web of Science ®Google Scholar
• Nagaraj K, Narendar D, Kishan V. Development of Olmesartan medoxomil optimized nanosuspension using Box-Behnken design to improve oral bioavailability. Drug Dev Ind Pharm. 2017;43(7):1186–1196.
   PubMed Web of Science ®Google Scholar
• Gustafsson J, Ljusberg-Wahren H, Almgren M, et al. Cubic lipid − water phase dispersed into submicron particles. Langmuir. 1996;12(20):4611–4613.
   Web of Science ®Google Scholar
• Jevprasesphant R, Penny J, Jalal R, et al. The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int J Pharm. 2003;252(1–2):263–266.
   PubMed Web of Science ®Google Scholar
• Kang M, Cho J, Shim B, et al. Bioavailability enhancing activities of natural compounds from medicinal plants. J Med Plants Res. 2009;3(13):1204–1211.
   Google Scholar
• Thakkar H, Parmar M, Patel A, et al. Studies on inclusion complex as potential systems for enhancement of oral bioavailability of olmesartan medoxomil. Chron Young Sci. 2012;3(2):129–136.
   Google Scholar
• Yadav A, Yadav D, Karekar P, et al. Enhanced solubility and dissolution rate of Olmesartan medoxomil using crystallo-coagglomeration technique. Der Pharmacia Sinica. 2012;3(2):160–169.
   Google Scholar
• Beg S, Rizwan M, Sheikh A, et al. Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol. 2011;63(2):141–163.
   PubMed Web of Science ®Google Scholar
• Sruthy P, Anoop K. Formulation and evaluation of olmesartan medoxomil floating tablets. Int J Pharm Pharm Sci. 2013;5:691–696.
   Google Scholar
• Abd-El Bary A, Louis D, Sayed S. Olmesartan medoxomil surface solid dispersion-based orodispersible tablets: formulation and in vitro characterization. J Drug Del Sci Tech. 2014;24(6):665–672.
   Web of Science ®Google Scholar
• Mora-Huertas C, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385(1–2):113–142.
   PubMed Web of Science ®Google Scholar
• Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Rel. 2004;95(3):627–638.
   PubMed Web of Science ®Google Scholar
• Arun B, Narendar D, Veerabrahma K. Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation. Artif Cells Nanomed Biotechnol. 2018;46(1):126–137.
   PubMed Web of Science ®Google Scholar
• Sasidhar R, Vidyadhara S, Maheswari G, et al. Solubility and dissolution rate enhancement of olmesartan medoxomil by complexation and development of mouth dissolving tablets. Advan Biol Res. 2013;7(2):32–41.
   Google Scholar
• Zakia B, Suyang Z, Wenli Z, et al. Formulation, development and bioavailability evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) of atorvastatin calcium. Int J Pharm. 2013;29:1103–1113.
   Google Scholar
• Badri W, Miladi K, Eddabra R, et al. Elaboration of nanoparticles containing indomethacin: argan oil for transdermal local and cosmetic application. J Nanomater. 2015;2015:1–9.
   Web of Science ®Google Scholar
• White B, Banerjee S, O’Brien S, et al. Zeta-potential measurements of surfactant-wrapped individual single-walled carbon nanotubes. J Phys Chem C. 2007;111(37):13684–13690.
   Web of Science ®Google Scholar
• Rima K, Dima M, Paolo Y. Polycaprolactone as drug carrier for an antifungal agent. J Drug Del Therapeutics. 2018;8(1):81–85.
   Google Scholar
• Azimi B, Nourpanah P, Rabiee M, et al. Poly (ε-caprolactone) fiber: an overview. J Eng Fibers Fabr. 2014;9(3):74–90.
   Web of Science ®Google Scholar
• Gombás Á, Szabó-Révész P, Regdon G, Jr, et al. Study of thermal behaviour of sugar alcohols. J Therm Anal Calorimetry. 2003;73(2):615–621.
   Web of Science ®Google Scholar
• Abdelwahed W, Degobert G, Stainmesse S, et al. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Delivery Rev. 2006;58(15):1688–1713.
   PubMed Web of Science ®Google Scholar